Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.60 |
| ▸ | NCF1 | P14598 | 12/20 | 0.50 |
| ▸ | CYBB | P04839 | 5/20 | 0.49 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22509627 | 1.00 | BACE1 (0.60) | BACE1NCF1CYBBNOX5NOS2 | |
| SCHEMBL29987443 | 0.79 | MAOA (0.40) | BACE1ADORA2ATYMS | |
| SCHEMBL3338347 | 0.79 | MAOA (0.40) | BACE1ADORA2ATYMS | |
| SCHEMBL6664318 | 0.78 | ADORA2A (0.38) | BACE1ADORA2ATYMS | |
| SCHEMBL29769305 | 0.78 | BACE1 (0.64) | BACE1NCF1CYBBNOX5NOS2 | |
| SCHEMBL3431601 | 0.78 | BACE1 (0.64) | BACE1NCF1CYBBNOX5NOS2 | |
| SCHEMBL13049644 | 0.75 | BACE1 (0.60) | BACE1NCF1CYBBNOX5NOS2 | |
| SCHEMBL3071480 | 0.75 | BACE1 (0.60) | BACE1NCF1CYBBNOX5NOS2 | |
| SCHEMBL3067674 | 0.75 | BACE1 (1.00) | BACE1NCF1CYBBNOX5NOS2 | |
| SCHEMBL1133378 | 0.75 | BACE1 (0.60) | BACE1NCF1CYBBNOX5NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | LUPIN LIMITED (IN) | 2024-04-09 | — | — | US | disclosed |
| EP-4048270-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITORS | Lupin Limited (IN) | 2022-08-31 | — | — | EP | disclosed |
| US-20220267339-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2022-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267339-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | BACE1 1210/4885NCF1 3660/4885CYBB 3898/4885 |
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | BACE1 1210/4885NCF1 3660/4885CYBB 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.